Nanomedicine offers promising strategies against infectious diseases, including advanced nanovaccines and nanoantibiotics to combat drug resistance.
By Arzoo PuriMar 14 2024Reviewed by Megan Craig, M.Sc. Infectious diseases are a major worldwide issue caused by viral, bacterial, parasitic, and fungal organisms with varied degrees of severity. When these agents are detected early, they can be prevented and treated, saving lives and money. Here, we explore the application of nanomedicine to fight infectious diseases.Introduction to Nanomedicine in Fighting Infectious Diseases Infectious and parasitic disorders account for 9.
Nanotechnology Solutions for Infectious Disease Control Nanotechnologies in medicine have tremendous potential for combating and treating infectious diseases, and their capabilities have been investigated for use in antiviral drug delivery, vaccine development, and pathogen identification. 2 Nanoparticle-based Drug Delivery Systems NPs can be used to transport medications, increasing efficacy and decreasing side effects. 5
The encapsulation of antimicrobial medicines into nanoparticle systems has significant promise for enhancing treatment efficacy while reducing adverse effects. Regulating particle size, surface characteristics, and drug release are important aims in nanoparticle design because they allow for location-specific action at optimum rates and dosages. 7
Related StoriesWang et al. demonstrated the novel use of inhalable hybrid nanovaccines. They created an inhalable nanovaccine to improve protective immunity against severe acute respiratory syndrome coronavirus 2 infection. 10 Nanoantibiotics have garnered immense interest in combating drug resistance observed in various pathogenic microorganisms against conventional antibiotics. Nanoparticle-delivered pharmaceuticals outperform free antibiotics at comparable doses in terms of bacterial growth inhibition, drug toxicity, and drug release duration. 12
PLLA provided biocompatibility and degradability, mPEG improved the stability and retention time of pyrinezolid. Pyrinezolid micelles had targeted lung aggregation and increased oral bioavailability , which was beneficial for the treatment of MRSA-associated pneumonia. 13